Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.

Amylyx Pharmaceuticals, Inc. Common Stock

Amylyx Pharmaceuticals, Inc. is a global company committed to the mission of discovery and development of treatments for relentless and progressing neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create #MoreMoments for the neurodegenerative disease community. Community Guidelines: https://bit.ly/3C1v1wz 

Please be aware of potential phishing scams imitating Amylyx. All authentic communications from Amylyx will be from the Amylyx.com domain.

The ALS Association

ALS Finding a Cure

Lysosomal Therapeutics

Morningside Group

ALS Investment Fund

Morningside Venture Investments

DRADS Capital

Woodline Partners

Marshall Wace

Perceptive Advisors

Polaris Founders Capital

Tybourne Capital Management

Verition Fund Management

683 CAPITAL

aMoon Fund

Belinda Termeer

Amylyx Pharmaceuticals

The work to support the global #neurodegenerative disease community never stops. Subscribe for the latest updates from Amylyx at www.amylyx.com. 

With a new year upon us, we’re eager to continue our fight of addressing the unmet needs of those with #ALS and other #neurodegenerative diseases. There is no time to waste.

Today we announced the first participant dosed in the largest #progressivesupranuclearpalsy study to date. This Phase 3 #clinicaltrial for the treatment of #PSP will enroll approximately 600 participants across ~100 sites in the U.S., Canada, the EU, the UK, and Japan.
Read more: https://lnkd.in/enCfTTKU 

As 2023 draws to a close, we’re also reflecting on 10 years of Amylyx. We’d like to show our gratitude to the incredible determination of the #ALS and #neurodegenerative community, as well as our extraordinary global colleagues who show up every day with the shared mission of one day ending the suffering caused by neurodegenerative diseases.

At Amylyx, we’ve created a culture that uses unconventional thinking for unsolved problems. We learn from one another through our collective experience, and we share a connection in our common purpose. 
Does this sound like you? 
See our current openings: https://lnkd.in/eDq_3vK4 

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	2.19M -	3.61M 64.60%	17.40M 381.48%	46.61M 167.93%	22.06M 52.67%
accumulated other comprehensive income loss			9K -	-86K 1,055.56%	197K 329.07%
cash and cash equivalents	3.06M -	12.88M 320.13%	96.12M 646.43%	346.94M 260.96%	170.20M 50.94%
cash and short term investments	3.06M -	12.88M 320.13%	96.12M 646.43%	346.94M 260.96%	371.36M 7.04%
common stock	1K -	1K 0%	1K 0%	7K 600%	7K 0%
deferred revenue
deferred revenue non current	4K -	14K 250%
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory				9.77M -	38.32M 292.29%
long term debt	14.93M -	1.43M 90.46%		4.24M -	1.98M 53.27%
long term investments					719K -
net debt	11.87M -	-11.45M 196.51%	-96.12M 739.31%	-340.67M 254.43%	-165.96M 51.28%
net receivables				15.31M -	40.05M 161.66%
other assets
other current assets			8.83M -	10.11M 14.49%	14.93M 47.64%
other current liabilities	2.33M -	3.71M 59.08%		-2.04M -	57.72M 2,929.61%
other liabilities
other non current assets	18K -	314K 1,644.44%	3.63M 1,056.05%	1.19M 67.36%	45.66M 3,753.00%
other non current liabilities	9.11M -	72.06M 690.78%	239.39M 232.19%
othertotal stockholders equity	276K -	1.19M 330.43%	-3.01M 353.20%	303.45M 10,188.20%	220.72M 27.26%
preferred stock			7.67M -	391.45M 5,000.36%	517.45M 32.19%
property plant equipment net		151K -	474K 213.91%	8.13M 1,616.24%	6.41M 21.19%
retained earnings	-25.63M -	-67.91M 164.94%	-155.84M 129.47%	-354.22M 127.29%	-304.95M 13.91%
short term debt				2.04M -	2.26M 10.64%
short term investments			45.93M -	284.42M 519.28%	201.16M 29.27%
tax assets
tax payables
total assets	3.22M -	14.10M 338.01%	105.61M 648.82%	391.45M 270.64%	517.45M 32.19%
total current assets	3.20M -	13.64M 325.95%	101.51M 644.26%	382.13M 276.45%	464.67M 21.60%
total current liabilities	4.53M -	7.33M 61.76%	17.40M 137.46%	46.61M 167.93%	82.04M 76.02%
total debt	14.93M -	1.43M 90.46%		6.28M -	4.24M 32.50%
total investments			45.93M -	284.42M 519.28%	201.16M 29.27%
total liabilities	28.58M -	80.83M 182.85%	256.78M 217.69%	50.85M 80.20%	84.02M 65.25%
total liabilities and stockholders equity	3.22M -	14.10M 338.01%	105.61M 648.82%	391.45M 270.64%	517.45M 32.19%
total non current assets	18K -	465K 2,483.33%	4.10M 782.58%	9.32M 127.10%	52.79M 466.39%
total non current liabilities	24.05M -	73.50M 205.65%	239.39M 225.68%	4.24M 98.23%	1.98M 53.27%
total stockholders equity	-25.36M -	-66.72M 163.14%	-151.17M 126.55%	340.61M 325.32%	433.43M 27.25%

COM:AMYLYX

Amylyx Pharmaceuticals, Inc.

Last Close

5.19

22/11 21:00

Market Cap

361.25M

Beta: -

Volume Today

831.95K

Avg: -

Preview